Currently out of the existing stock ratings of Ross Osborn, 106 are a BUY (92.98%), 8 are a HOLD (7.02%).

Ross Osborn

Work Performance Price Targets & Ratings Chart

Analyst Ross Osborn, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 33.56% that have a potential upside of 48.26% achieved within 126 days.

Ross Osborn’s has documented 220 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on XGN, Exagen at 15-May-2025.

Wall Street Analyst Ross Osborn

Analyst best performing recommendations are on CVRX (CVRX).
The best stock recommendation documented was for NPCE (NEUROPACE) at 5/14/2025. The price target of $17 was fulfilled within 1 day with a profit of $1.4 (8.97%) receiving and performance score of 89.74.

Average potential price target upside

of $7.27 (139.28%) on AXGN (AXOGEN).
of $6.45 (85.21%) on NPCE (NEUROPACE).
of $4.92 (56.44%) on CVRX (CVRX).

PACB Pacific Biosciences of California SIBN Si-Bone SPNE SeaSpine Holdings Corp NYXH Nyxoah ASXC Asensus Surgical AXGN Axogen MYNZ Mainz Biomed BV PAVM PAVmed RCEL Avita Medical Ltd XGN Exagen AZYO Aziyo Biologics LUCD Lucid Diagnostics NNOX Nano X Imaging Ltd ORGO Organogenesis Holdings CERS Cerus CVRX CVRx MDXG MiMedx Group NPCE Neuropace PRE Prenetics Global Ltd SMTI Sanara Medtech

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Luke Sergott (BARCLAYS)